Alex Ling

Excited to share our latest work with the stellar GBM TeamLab at Break Through Cancer. We longitudinally sampled GBM tumors through 4 months of oHSV treatment and applied multi-omic profiling to understand the impact of the therapy over space and time. science.org/doi/10.1126/sc…

Oops, had to repost to fix a typo :P

Excited to share our phase I clinical results for CAN-3110, an oncolytic HSV1, in recurrent glioma. We saw some nice immune recruitment that was associated with survival--especially in patients who had pre-existing HSV1 serology: nature.com/articles/s4158…

Perturb-seq at genome scale predicts the function of poorly characterized genes. #NBThighlight cell.com/cell/fulltext/…

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines dlvr.it/RnnsBZ

Our newest predictive model for drug combination efficacy, and further evidence that a significant portion of the clinical efficacy of cancer drug combinations can be explained by independent drug action. Looking forward to hearing everyone's thoughts.